Home

Among the critical areas of cancer research, breast cancer remains a leading concern, and HMGB1 protein is increasingly recognized as a key player in its progression.

On the just occurred World Cancer Day, we had the opportunity to reflect on the growing body of research in cancer development, immune modulation, and drug resistance.

A recent study has revealed that HMGB1 dimerization is a key player in immune signaling. When two HMGB1 molecules join through a Cys106–Cys106 disulfide bond, their #inflammatory potential intensifies.

Two recent studies shed light on how HMGB1 contributes to Kaposi’s sarcoma (KS) and small cell lung cancer (SCLC), revealing new potential therapeutic strategies for cancer.

In 2025 HMGBiotech Srl proudly marks its 20th anniversary, a milestone that reflects two decades of dedication to advancing research on HMGB1 protein.

A recent study highlights how higher HMGB1 levels correlate with liver fibrosis progression in individuals with HIV-HBV co-infection, despite suppressive antiretroviral therapy (ART).

Elevated HMGB1 levels are strongly associated with epilepsy severity and drug resistance, making it a valuable biomarker for clinical research. A recent study has demonstrated the potential of HMGB1-targeted interventions.

A recent research has highlighted how HMGB1 (High Mobility Group Box 1) protein in its reduced form plays a crucial role in enhancing cancer cell migration and invasiveness through its interaction with the chemokine CXCL12.

The role of High Mobility Group Box Protein 1 (HMGB1) is increasingly emerging in diabetes-associated complications, particularly diabetic encephalopathy (DE) and diabetic kidney disease (DKD).